Healthcare
National Research Corporation(NRC)
Live Price
Offline$18.54
+4.45% today
1Y Change
+10.10%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $390.00M
- Revenue Growth
- -4.0%
- EPS Growth
- -50.5%
- Dividend Yield
- 3.2%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
National Research Corporation (NRC) is a Healthcare stock with a market cap of $390.00M and listed on NASDAQ. The stock last traded around $18.54 and up 10.1% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of -4.0%, EPS growth of -50.5%, a dividend yield of 3.2%. What stands out right now is revenue -4.0%, EPS -50.5%, free cash flow -17.9% with operating margin 14.1% and ROIC 12.2%. The dividend matters to the case here, with a current yield around 3.2%. Valuation already assumes a fairly strong business story at P/E 42.0 and price/sales 2.8. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines NRC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-4.0% vs +7.6% peer median
Operating Margin
Below sector median
+14.1% vs +19.4% peer median
P/E
Above sector median
42.0 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -4.0% and EPS is at -50.5%, with operating margin around 14.1%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 3.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.8% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | -4.7% | +2.4% | +1.6% |
2026 Apr 27, 2026 | โ | -1.6% | +6.5% | +11.3% |
2026 Feb 3, 2026 | โ | -13.3% | -17.4% | -25.5% |
Benchmark Edge
NRC vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NRC
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NRC Max Drawdown
-46.49%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NRC and SPY.
Company Overview
National Research Corporation
NASDAQ Global Select
National Research Corporation provides analytics and insights that facilitate measurement and enhancement of the patient and employee experience in the United States and Canada. Its portfolio of subscription-based solutions provides actionable information and analysis to healthcare organizations across a range of mission-critical, constituent-related elements, including patient experience, service recovery, care transitions, health risk assessments, employee engagement, reputation management, and brand loyalty. The company also offers market insights solutions that allow the tracking of awareness, perception, and consistency of healthcare brands; assessment of competitive differentiators; and enhanced segmentation tools to evaluate needs, wants, and behaviors of communities through real-time competitive assessments and enhanced segmentation tools. In addition, it provides experience solutions, such as patient and resident experience, workforce engagement, health risk assessments, transitions, and improvement tools. Further, the company offers health risk assessment solutions that enable clients to segment populations and manage care for those who are most at risk, engage individuals, enhance preventative care, and manage wellness programs; and transitions solutions, which enable organizations to identify and manage high-risk patients to reduce readmissions, enhance patient satisfaction and support safe care transitions. Additionally, it provides transparency solutions that allow healthcare organizations to share picture of their organization and ensure content informs in consumer decision-making; and governance solutions for not-for-profit hospital and health system boards of directors, executives, and physician leadership. The company serves integrated health systems, post-acute providers, and payer organizations. National Research Corporation was founded in 1981 and is headquartered in Lincoln, Nebraska.
- Leadership
- Trent Green
- IPO Date
- May 23, 2013
- Employees
- 368
- Street Address
- 1245 Q Street
- Mailing
- Lincoln, NE, 68508
- Region
- Lincoln, NE, US
- Reporting Currency
- USD
- Investor Line
- 402 475 2525
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 42.0
- EV/EBITDA
- 16.8
- Price/Sales
- 2.8
- Price/Book
- 28.1
Growth
- Revenue
- -4.0%
- EPS
- -50.5%
- Free Cash Flow
- -17.9%
Profitability
- Gross Margin
- 55.9%
- Operating Margin
- 14.1%
- Net Margin
- 6.5%
- ROE
- 57.2%
- ROIC
- 12.2%
Balance Sheet
- Debt/Equity
- 5.78
- Current Ratio
- 0.52
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.